Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer

Journal of Pathology

Volumn 228, Issue 1, 2012, Pages 31-44

  Carvalho, Joana ^a,b   Van Grieken, Nicole C ^c   Pereira, Patricia M ^d   Sousa, Sõnia ^a   Tijssen, Marianne ^c   Buffart, Tineke E ^c   Diosdado, Begoña ^c   Grabsch, Heike ^e   Santos, Manuel A S ^d   Meijer, Gerrit ^c   Seruca, Raquel ^a,b   Carvalho, Beatriz ^c   Oliveira, Carla ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AVEIRO   (Portugal)

^e UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

E cadherin (CDH1); enhancer of Zeste homologue 2 (EZH2); gastric cancer; microRNA 101

Indexed keywords

MICRORNA 101; TRANSCRIPTION FACTOR EZH2; UVOMORULIN;

ALLELE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FUNCTIONAL DISEASE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENOMICS; HUMAN; HUMAN TISSUE; INTESTINE CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; STOMACH CANCER; STOMACH MUCOSA; UPREGULATION;

CADHERINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84864749110     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4032     Document Type: Article

References (59)

1. Parkin DM, Bray F, Ferlay J, et al., Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Khushalani N,. Cancer of the esophagus and stomach. Mayo Clin Proc 2008; 83: 712-722.
3. Carneiro F, Oliveira C, Leite M, et al., Molecular targets and biological modifiers in gastric cancer. Semin Diagn Pathol 2008; 25: 274-287.
4. Guilford P, Hopkins J, Harraway J, et al., E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
5. Grady WM, Willis J, Guilford PJ, et al., Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26: 16-17.
6. Oliveira C, Senz J, Kaurah P, et al., Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009; 18: 1545-1555.
7. Oliveira C, Sousa S, Pinheiro H, et al., Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009; 136: 2137-2148.
8. Oliveira C, Bordin MC, Grehan N, et al., Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002; 19: 510-517.
9. Liu YC, Shen CY, Wu HS, et al., Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas. World J Gastroenterol 2006; 12: 2168-2173.
10. Machado JC, Oliveira C, Carvalho R, et al., E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001; 20: 1525-1528.
11. Machado JC, Soares P, Carneiro F, et al., E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79: 459-465.
12. Berx G, Becker KF, Hofler H, et al., Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-237.
13. Becker KF, Atkinson MJ, Reich U, et al., E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852.
14. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al., E-cadherin expression as a differentiation marker in gastric cancer. Hepatogastroenterology 1998; 45: 2437-2442.
15. von Burstin J, Eser S, Paul MC, et al., E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009; 137: 361-371, e361-365.
16. Ma L, Young J, Prabhala H, et al., miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
17. Banerjee R, Mani RS, Russo N, et al., The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30: 4339-4349.
18. Cao R, Wang L, Wang H, et al., Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
19. Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al., Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 2893-2905.
20. Cao R, Zhang Y,. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-164.
21. Cao Q, Yu J, Dhanasekaran SM, et al., Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27: 7274-7284.
22. Fujii S, Ochiai A,. Enhancer of Zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 2008; 99: 738-746.
23. Varambally S, Dhanasekaran SM, Zhou M, et al., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
24. Bachmann IM, Halvorsen OJ, Collett K, et al., EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-273.
25. Matsukawa Y, Semba S, Kato H, et al., Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97: 484-491.
26. Kidani K, Osaki M, Tamura T, et al., High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45: 39-46.
27. Rao ZY, Cai MY, Yang GF, et al., EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGFβ1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010; 31: 1579-1583.
28. Collett K, Eide GE, Arnes J, et al., Expression of enhancer of Zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 1168-1174.
29. Wagener N, Holland D, Bulkescher J, et al., The enhancer of Zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008; 123: 1545-1550.
30. Fussbroich B, Wagener N, Macher-Goeppinger S, et al., EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 6: e21651.
31. Li X, Zhang Y, Ding J, et al., Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2009; 59: 579-585.
32. Ueda T, Volinia S, Okumura H, et al., Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
33. Smits M, Nilsson J, Mir SE, et al., miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1: 710-720.
34. Strillacci A, Griffoni C, Sansone P, et al., MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315: 1439-1447.
35. Su H, Yang JR, Xu T, et al., MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.
36. Wang HJ, Ruan HJ, He XJ, et al., MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 2010; 46: 2295-2303.
37. Varambally S, Cao Q, Mani RS, et al., Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
38. Friedman JM, Liang G, Liu CC, et al., The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623-2629.
39. Cao P, Deng Z, Wan M, et al., MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol Cancer 2010; 9: 108.
40. Gartner F, David L, Seruca R, et al., Establishment and characterization of two cell lines derived from human diffuse gastric carcinomas xenografted in nude mice. Virchows Arch 1996; 428: 91-98.
41. Buffart TE, Tijssen M, Krugers T, et al., DNA quality assessment for array CGH by isothermal whole genome amplification. Cell Oncol 2007; 29: 351-359.
42. Pereira PM, Marques JP, Soares AR, et al., MicroRNA expression variability in human cervical tissues. PLoS One 2010; 5: e11780.
43. t method. Methods 2001; 25: 402-408.
44. Joana Figueiredo JS-C, Ola Soderberg, Gianpaolo Suriano, et al., ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS ONE 2011; 6.
45. Karam R, Carvalho J, Bruno I, et al., The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene 2008; 27: 4255-4260.
46. Li S, Fu H, Wang Y, et al., MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009; 49: 1194-1202.
47. Kim K, Lee HC, Park JL, et al., Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics 2011; 6: 740-751.
48. Tanaka T, Arai M, Wu S, et al., Epigenetic silencing of microRNA-373 plays an important role in regulating cell proliferation in colon cancer. Oncol Rep 2011; 26: 1329-1335.
49. Tsuruta T, Kozaki KI, Uesugi A, et al., miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71: 6450-6462.
50. Kottakis F, Polytarchou C, Foltopoulou P, et al., FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 2011; 43: 285-298.
51. Hao Y, Gu X, Zhao Y, et al., Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 2011; 4: 1073-1083.
52. Buechner J, Tomte E, Haug BH, et al., Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011; 105: 296-303.
53. Chiang CW, Huang Y, Leong KW, et al., PKCα-mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci 2010; 17: 35.
54. Yu J, Cao Q, Mehra R, et al., Integrative genomics analysis reveals silencing of β-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007; 12: 419-431.
55. Fujii S, Ito K, Ito Y, et al., Enhancer of Zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008; 283: 17324-17332.
56. Shun CT, Wu MS, Lin JT, et al., An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology 1998; 45: 944-949.
57. Nikoloski G, Langemeijer SM, Kuiper RP, et al., Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
58. Ernst T, Chase AJ, Score J, et al., Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.2.
59. Buffart TE, Carvalho B, Hopmans E, et al., Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 2007; 211: 45-51.